CLINICAL TRIALS PROFILE FOR TOBI PODHALER

« Back to Dashboard

All Clinical Trials for TOBI PODHALER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02102152 ↗	Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection	Unknown status	Rabin Medical Center	N/A	2014-04-01	The use of inhaled medications for the treatment of pulmonary diseases allows for the delivery of a high concentration of a drug at the site of disease with reduced systemic absorption and risk of systemic adverse effects. Inhaled Tobramycin has been successfully used in the maintenance treatment of CF patients with chronic colonization with PA (Pseudomonas aeruginosa). In the CF population TOBI has been proven to improve lung functions, decrease the density of the PA in the sputum, decrease hospitalizations, and reduce the risk of mortality. Non CF Bronchiectasis share many features in common with CF, including frequent colonization with PA that leads to deterioration in lung function and increased morbidity. A recent Cochrane review concluded that there is a small benefit for the use of prolonged antibiotics in the treatment of bronchiectasis, however further randomized controlled trials with adequate power and standardized end points are required. There have been reports in the literature describing the efficacy of inhaled tobramycin the treatment of patients with non CF bronchiectasis with eradication of PA, and significant improvement in respiratory symptoms. There were however patients who discontinued treatment due to adverse events most commonly cough wheezing and dyspnea. (Scheinberg and Shore, Chest 2005). TOBI Podhaler is a dry powder inhaler that was recently launched, and is much easier and faster to use compared to nebulised Tobramycin. To the best of our knowledge Tobramycin dry powder formulation has not yet been trialed in patients with non CF bronchiectasis. The purpose of this trial is to assess the efficacy and tolerability of TOBI Podhaler in patients with non CF bronchiectasis, and to gather more data on the benefit of continuous antibiotic therapy in patients with non CF bronchectais.
NCT02113397 ↗	Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung	Terminated	Novartis Pharmaceuticals		2014-04-01	The purpose of this study is to characterize bacterial diversity and richness in the sputum of cystic fibrosis patients treated with every-other-month TOBI™ Podhaler™ and continuous alternating therapy with TOBI™ Podhaler and colistimethate (Colistin).
NCT02113397 ↗	Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung	Terminated	Dartmouth-Hitchcock Medical Center		2014-04-01	The purpose of this study is to characterize bacterial diversity and richness in the sputum of cystic fibrosis patients treated with every-other-month TOBI™ Podhaler™ and continuous alternating therapy with TOBI™ Podhaler and colistimethate (Colistin).
NCT02178540 ↗	Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients	Completed	Novartis Pharmaceuticals	Phase 4	2014-08-01	The purpose of this actual use human factors (HF) study is to validate the approved US TOBI Podhaler Instructions for Use (IFU), by establishing that the IFU effectively communicates the information necessary to achieve safe and effective use of the Podhaler device.
NCT02207426 ↗	Pharmacokinetic and Pharmacoscintigraphic Comparison of TobrAir® 6.0 With TOBI® and TOBI® Podhaler™	Completed	Pharmaero ApS	Phase 1	2014-07-01	This study compares pharmacokinetic profiles of tobramycin delivered by TobrAir® 6.0 device with TOBI® nebulizer system and the TOBI® Podhaler™ device. In addition, lung deposition of tobramycin delivered by TobrAir® 6.0 device and by TOBI® nebulizer system will be determined.
NCT02449031 ↗	Observational Study in Cystic Fibrosis Patients Using TOBI® Podhaler™ or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs	Active, not recruiting	Cystic Fibrosis Foundation		2015-05-05	This is a multicenter, prospective, two cohort, observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection.The study will collect data over 1 year on respiratory function, antibacterial effectiveness, and clinical outcomes of treatment with inhaled antipseudomonal antibiotics and data over 5 years on microbiological and safety assessments.
NCT02449031 ↗	Observational Study in Cystic Fibrosis Patients Using TOBI® Podhaler™ or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs	Active, not recruiting	Cystic Fibrosis Foundation Therapeutics		2015-05-05	This is a multicenter, prospective, two cohort, observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection.The study will collect data over 1 year on respiratory function, antibacterial effectiveness, and clinical outcomes of treatment with inhaled antipseudomonal antibiotics and data over 5 years on microbiological and safety assessments.

Clinical Trial Conditions for TOBI PODHALER

Condition Name

Condition Name for TOBI PODHALER
Intervention	Trials
Cystic Fibrosis	4
Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa	1
Cystic Fibrosis With Pulmonary Manifestations	1
Healthy	1

Condition MeSH

Condition MeSH for TOBI PODHALER
Intervention	Trials
Cystic Fibrosis	6
Fibrosis	5
Pseudomonas Infections	2
Infections	1

Clinical Trial Locations for TOBI PODHALER

Trials by Country

Trials by Country for TOBI PODHALER
Location	Trials
United States	48
Israel	1
Netherlands	1
United Kingdom	1

Trials by US State

Trials by US State for TOBI PODHALER
Location	Trials
Oklahoma	3
Ohio	3
Florida	3
Texas	2
New York	2

Clinical Trial Progress for TOBI PODHALER

Clinical Trial Phase

Clinical Trial Phase for TOBI PODHALER
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for TOBI PODHALER
Clinical Trial Phase	Trials
Completed	4
Recruiting	1
Terminated	1

Clinical Trial Sponsors for TOBI PODHALER

Sponsor Name

Sponsor Name for TOBI PODHALER
Sponsor	Trials
Novartis Pharmaceuticals	4
Mylan Inc.	2
Cystic Fibrosis Foundation Therapeutics	1

Sponsor Type

Sponsor Type for TOBI PODHALER
Sponsor	Trials
Industry	7
Other	6

Last updated: July 28, 2026

TOBI Podhaler Clinical Trials Update, Market Analysis, and Market Projection (Tobramycin Inhalation Powder)

Executive summary: TOBI Podhaler (tobramycin inhalation powder; Chiesi) targets cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection. Public clinical trial updates for the brand are limited in recent years, with most post-approval activity focused on label support, real-world uptake, and life-cycle work rather than large, new Phase 3 programs. Near-term revenue is driven by CF population trends, reimbursement access, institutional formularies, and conversion between inhaled tobramycin formats (solution, powder, and competing inhaled anti-pseudomonal regimens). A credible market projection requires tying demand to CF treated prevalence and conversion to inhaled delivery systems; based on available public information in the record, detailed, drug-specific revenue forecasts are not available for TOBI Podhaler alone in a way that supports a complete numeric projection.

What is TOBI Podhaler and how is it used in cystic fibrosis?

TOBI Podhaler is an inhaled dry-powder tobramycin product for CF patients with chronic pulmonary P. aeruginosa infection. The regimen is designed for repeated on-off cycles to reduce bacterial load and help manage lung function decline.

What patient population does it target?

• CF with chronic P. aeruginosa colonization
• Patients eligible for inhaled anti-pseudomonal maintenance therapy

How does Podhaler compare with other tobramycin inhaled products?

Key competitive comparisons in CF typically include:

• Inhaled tobramycin solution (nebulized)
• Alternative inhaled anti-pseudomonal agents (other antibiotics and adjunct anti-biofilm or anti-infective strategies)
• Delivery system switching driven by device preference, adherence, and payer coverage

What clinical trials have been updated for TOBI Podhaler recently?

No complete, fully auditable recent clinical-trials update set is available in the provided record that would support an accurate, date-stamped “what changed” summary for the brand’s current Phase 2/3 pipeline, endpoints, enrollment status, and readouts.

What trial types typically drive life-cycle updates for inhaled CF antibiotics?

Where brands do update, the work usually falls into:

• Bridging studies for device or formulation changes
• Pharmacokinetic (PK) and tolerability studies across subpopulations
• Real-world evidence studies supporting persistence, adherence, and hospitalizations
• Label expansions tied to regimen variations

What endpoints matter for inhaled tobramycin in CF?

• CF lung function measures (commonly FEV1)
• Sputum bacterial density and microbiology outcomes
• Exacerbation rates and time to exacerbation
• Safety tolerability (including ototoxicity and nephrotoxicity monitoring practices)

What is the current commercial setup for TOBI Podhaler in CF?

TOBI Podhaler competes in a patient-segment market where treatment choice depends on:

• Device usability (powder inhalation vs nebulization)
• Time-on-therapy and adherence
• Payer step edits and prior authorization requirements
• Clinical guidelines and local protocol

Key commercial drivers

• Treated CF population and chronic Pseudomonas prevalence
• Switch-rate between inhaled tobramycin solution and powder
• Uptake of alternative inhaled regimens and shifts in guideline language
• Channel mix: specialty pharmacy, hospital outpatient, and managed care coverage

Key friction points

• Coverage restrictions tied to CF severity criteria
• Pharmacy benefit design that changes net pricing across plans
• Patient ability to generate adequate inhalation flow for dry powder devices

Who are the competitors to TOBI Podhaler and how does the competitive landscape affect pricing?

TOBI Podhaler sits in the “inhaled maintenance anti-pseudomonal” competitive arena. Competitive pressure typically comes from:

• Other inhaled tobramycin formats
• Other inhaled anti-pseudomonal antibiotics
• Broader CF anti-infective strategies that shift clinician prescribing patterns

What matters most in substitution

• Equivalent efficacy perceptions for bacterial load suppression and lung function support
• Safety and monitoring burden compared with alternatives
• Device and adherence outcomes in practice settings
• Payer contracting and formulary placement

How does TOBI Podhaler market size and growth typically scale over time?

A practical market projection for TOBI Podhaler should be anchored to:

• CF population growth (diagnosis rates, survival improvements, and treated prevalence)
• Proportion of CF patients with chronic P. aeruginosa
• Persistence on inhaled anti-pseudomonal maintenance regimens
• Share-of-therapy assigned to inhaled tobramycin powder vs other options

What would scale demand upward?

• Increasing diagnosed CF population
• Rising chronic Pseudomonas prevalence in treated cohorts
• Increasing preference for inhaled powder delivery for adherence and reduced administration time

What would cap demand?

• Higher uptake of alternative inhaled regimens
• Payer restrictions limiting to specific CF severity thresholds
• Patient switching to nebulized alternatives due to device accessibility or reimbursement

When does TOBI Podhaler face generic or biosimilar substitution risk?

No complete, auditable exclusivity and patent-expiration dataset is available in the provided record to produce a legally precise “generic entry risk” timeline (including Orange Book listings, patent numbers, expiration dates, and any Paragraph IV litigation status). A numeric or date-driven exclusivity forecast cannot be issued from the provided inputs.

What is the Orange Book status of TOBI Podhaler?

No Orange Book listing details are available in the provided record to compile:

• Listed patents
• Expiration dates
• Exclusivity codes
• Proprietary formulation or method-of-use patent mapping

What patent litigation or settlements affect TOBI Podhaler commercialization?

No litigation/settlement docket information is available in the provided record sufficient to summarize:

• Parties and case numbers
• Alleged generic ANDA challenges
• Hearing dates, decisions, or settlement triggers
• Impact on launch timing

How strong is the patent estate for TOBI Podhaler across formulations and methods?

No patent estate dataset is available in the provided record to quantify strength using:

• Patent count by category (composition/formulation/method)
• Remaining term by jurisdiction
• Litigation posture and enforceability indicators

What formulation and delivery-system issues drive clinical and commercial performance for TOBI Podhaler?

TOBI Podhaler is an inhaled dry-powder formulation, which makes device reliability and inhalation technique central to real-world performance.

What technical factors influence outcomes

• Inhalation flow rate and patient technique training
• Dose consistency and inhaler handling
• Lung deposition efficiency in CF patients with mucus burden
• Tolerability and bronchospasm management practices

What is the regulatory status for TOBI Podhaler (FDA and other jurisdictions)?

No FDA regulatory milestones or supplemental approval history is available in the provided record to provide:

• Latest label revisions
• Section 505(b)(2) vs 505(j) procedural context
• Postmarketing commitments status

Market projection for TOBI Podhaler: baseline, upside, downside scenarios

A complete numeric projection requires a drug-specific demand model and monetization assumptions (net pricing, persistence, formulary share). The provided record does not contain the necessary auditable market inputs to produce those numbers for TOBI Podhaler alone.

Projection logic that would be used (structure)

• Treated CF population forecast
• Chronic Pseudomonas prevalence and eligibility rate
• Inhaled anti-pseudomonal regimen adoption rate
• Share of tobramycin powder vs alternatives
• Persistence (cycle adherence)
• Net price evolution based on payer mix and competition

Scenario definitions (qualitative)

• Baseline: stable CF treated growth and modest share stability for tobramycin powder
• Upside: faster adoption of powder delivery and slower migration to competitors
• Downside: increased payer restriction and faster switching to alternative inhaled regimens

Key Takeaways

• TOBI Podhaler is a maintenance inhaled tobramycin option for CF patients with chronic P. aeruginosa, with commercial demand driven by CF treated prevalence, chronic colonization, and payer coverage.
• Public clinical-trial “updates” for TOBI Podhaler cannot be compiled into a date-stamped, endpoint-level progress report from the provided record.
• A numeric market projection for TOBI Podhaler is not supportable from the provided record because drug-specific audited inputs (revenues, unit demand, net pricing trajectory, exclusivity timeline, and patent/ANDA status) are not available.

FAQs

1. What patient factors most influence TOBI Podhaler adherence and persistence in real-world CF care?
2. How do inhaled tobramycin powder dosing cycles compare with nebulized tobramycin in clinician prescribing behavior?
3. What are the main payer coverage criteria that typically determine TOBI Podhaler access for CF patients?
4. Which inhaled anti-pseudomonal alternatives most frequently substitute for tobramycin in CF formularies?
5. What device-handling or inhalation-technique issues are associated with dry-powder inhaled antibiotics in CF populations?

References

1. (No cited sources were provided in the prompt record.)